Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14670188 | 0.98 | CA2 (0.52) | CA2CA1FAAHRELAMEN1 | |
| SCHEMBL5893741 | 0.92 | — | — | |
| SCHEMBL17898070 | 0.81 | — | — | |
| SCHEMBL301013 | 0.79 | FAAH (0.50) | CA2CA1FAAHRELA | |
| SCHEMBL4565920 | 0.79 | FAAH (0.50) | CA2CA1FAAHRELA | |
| SCHEMBL6501307 | 0.77 | FAAH (0.54) | CA2FAAHRELA | |
| SCHEMBL10226704 | 0.77 | FAAH (0.54) | CA2FAAHRELA | |
| SCHEMBL1679040 | 0.77 | FAAH (0.48) | CA2FAAHRELA | |
| SCHEMBL29166790 | 0.76 | RELA (0.43) | CA2CA1FAAHRELAMEN1 | |
| SCHEMBL667725 | 0.76 | FAAH (0.43) | CA2CA1FAAHRELAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105820096-A | Method for preparing substituted ethyl aryl sulfone | 清华大学 | 2016-08-03 | — | — | CN | disclosed |
| US-20070275935-A1 | Estratriene Derivatives | CRYPTOPHARMA PTY LTD (AU) | 2007-11-29 | — | — | US | disclosed |
| EP-1625143-A1 | ESTRATRIENE DERIVATIVES | Cryptopharma Pty Ltd (AU) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101595-A1 | ESTRATRIENE DERIVATIVES | CRYPTOPHARMA PTY LTD (AU) | 2004-11-25 | — | — | WO | disclosed |
| US-20030073682-A1 | Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors | VOSS MATTHEW E (US) | 2003-04-17 | — | — | US | disclosed |
| US-6365587-B1 | FOR THERAPY OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, MULTIPLE SCLEROSIS, NEURODEGENERATIVE DISEASES, PSORIASIS, AUTOIMMUNE DISEASE, CROHN'S DISEASE, INFLAMMATORY BOWEL DISEASE, OR HIV | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-02 | — | — | US | disclosed |
| EP-1077978-A1 | NOVEL SUBSTITUTED ARYL HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058531-A1 | NOVEL SUBSTITUTED ARYL HYDROXAMIC ACIDS AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275935-A1 | Estratriene Derivatives | ESR2, ESRRB, NR3C2 | CA2 3030/4885CA1 4457/4885FAAH 2386/4885 |
| US-20030073682-A1 | Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors | MMP3, MMP10, MMP2 | CA2 54/4885CA1 83/4885FAAH 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.